Huons Global Co., Ltd.
084110.KQ · KOE
Company research
Huons Global Co., Ltd. (084110.KQ) is a South Korea-based holding company headquartered in Seongnam-si that operates as the parent of a pharma-based global healthcare group, with key subsidiaries including Huons (pharmaceuticals), Humedix (aesthetics and medical devices), and Huons BioPharma (botulinum toxin). Founded in 1965 and listed on the KOSDAQ exchange since 2006, the company transitioned to a holding company structure in 2016, generating revenue primarily through dividends, management consulting fees, brand fees, and rental income from its affiliates. The group's diversified portfolio spans ethical pharmaceutical drugs (oral solids and injectables across a wide range of therapeutic areas), medical devices, ophthalmic preparations, biological products, cosmetics, and health supplements, with a presence in over 30 countries including the United States, Japan, Vietnam, Latin America, the Middle East, Africa, and Europe. Huons Global is notably recognized for pioneering Korea's first plastic injectable products in 1993 and received U.S. FDA approval for a generic lidocaine local anesthetic injection in 2018, underscoring its commitment to innovation and global market expansion.
Research reports
Independent multi-model valuation report concluding Huons Global is roughly 302% undervalued versus its consensus fair value estimate, supported by strong revenue growth, a high quality score, and detailed fundamental metrics, while cautioning that deeply discounted prices can still be value traps if data quality or business fundamentals deteriorate.
ValueInvesting.io · June 3, 2026084110.KQ Fair ValueApplies Peter Lynch’s fair value formula to Huons Global and finds intrinsic value far below the current share price, concluding the stock is “not a good investment” with an expected loss of about 62% if bought at prevailing levels, and explaining the earnings-growth assumptions and sensitivity to volatile historical net income.
KoalaGains · December 1, 2025Huons Global Co., Ltd. (084110) Fair Value AnalysisDeep-dive valuation and factor analysis (as of December 1, 2025) judging Huons Global generally fairly valued with modest upside, balancing a discounted price-to-book and reasonable EV/EBITDA against an elevated P/E, volatile EPS and stretched EV/sales, while highlighting improving free cash flow, a moderate but sustainable dividend, and the mixed implications of recent momentum for future returns.